BioLineRx (BLRX) Debt to Equity (2015 - 2025)
BioLineRx (BLRX) recorded quarterly Debt to Equity of $0.49 in Q4 2025, down 50.79% quarter-over-quarter from $1.0 in Q4 2024, and down 50.79% on a YoY basis from $1.0 in Q4 2024.
BioLineRx (BLRX) Debt to Equity (2015 - 2025) Analysis & Trends
BioLineRx's Debt to Equity history runs 8 years deep, the most recent figure standing at $0.49 for Q4 2025.
- In Q4 2025, Debt to Equity fell 50.79% year-over-year to $0.49; the TTM figure through Dec 2025 stood at $0.49 (down 50.79% YoY), while the FY2025 annual figure was $0.49, down 50.79% from the prior year.
- Debt to Equity was $0.49 for Q4 2025 at BioLineRx, down from $1.0 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.0 in Q4 2024 to a low of $0.49 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | 0.49 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.49 |
| Dec 31, 2024 | 1.00 |
| Dec 31, 2020 | 0.26 |
| Dec 31, 2019 | 0.25 |
| Dec 31, 2018 | 0.21 |
| Dec 31, 2017 | 0.00 |
| Dec 31, 2016 | 0.01 |
| Dec 31, 2015 | 0.01 |